Successful discontinuation of BZDs‐ post treatment Objective and subjective · patients with BZD harmful use, abuse or dependence
CBT (plus taper) probably leads to higher successful discontinuation of BZDs‐ post treatment Objective and… compared with taper (moderate certainty).
1 finding from 1 review
Successful discontinuation of BZDs‐ 12 month · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in successful discontinuation of BZDs‐ 12 month compared with taper (moderate certainty).
1 finding from 1 review
Reduce BZDs> 50% ‐ post treatment Objective · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in reduce BZDs> 50% ‐ post treatment Objective compared with taper (low certainty).
1 finding from 1 review
Reduce BZDs> 50% ‐ 12 month · patients with BZD harmful use, abuse or dependence
CBT (plus taper) showed no clear difference in reduce BZDs> 50% ‐ 12 month compared with taper (low certainty).
1 finding from 1 review
Depression at endpoint · Post‐TBI Depression
It is very uncertain whether CBT changes depression scales (BDI‐II, HAM‐D and HADS); higher score means more… compared with wait‐list control (very low certainty).
1 finding from 1 review
Depressive symptoms · Post‐TBI Depression
It is very uncertain whether CBT changes beck Depression Inventory (BDI); higher score means more depressed compared with supportive Psychotherapy (very low certainty).
1 finding from 1 review
Global state: Improved to any extent · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Service use: Admitted · patients with schizophrenia
1 finding from 1 review
Number of participants with improved quality of life · patients with schizophrenia
1 finding from 1 review
Satisfaction with treatment: Improved to any extent · patients with schizophrenia
1 finding from 1 review
Economic outcomes · patients with schizophrenia
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
It is very uncertain whether non‐TFCBT changes leaving the study early due to any reason compared with waitlist/Usual Care (very low certainty).
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review
Leaving the study early · Adults with PTSD for at least 3 months
It is very uncertain whether group TFCBT changes leaving the study early for any reason compared with waitlist/Usual Care (very low certainty).
1 finding from 1 review
Severity of PTSD symptoms ‐ Clinician‐rated · Adults with PTSD for at least 3 months
1 finding from 1 review